FRAMINGHAM, Mass., March 7, 2014 /PRNewswire/ -- HeartWare
International, Inc. (NASDAQ:HTWR), a leading innovator of less
invasive, miniaturized circulatory support technologies that are
revolutionizing the treatment of advanced heart failure, today
announced that CEO Doug Godshall is
scheduled to present at the 2014 Barclays Global Healthcare
Conference at 10:15 a.m. EDT on
Tuesday, March 11, 2014. The
conference is being held March 11-13
at Loews Miami Hotel.
A live webcast of the Company's presentation at the conference
will be available via a link provided at www.heartware.com. A
replay of the webcast will be available for 90 days at the site
after the presentation.
About HeartWare International
HeartWare International
develops and manufactures miniaturized implantable heart pumps, or
ventricular assist devices, to treat Class IIIB / IV patients
suffering from advanced heart failure. The HeartWare®
Ventricular Assist System features the HVAD® pump, a
small full-support circulatory assist device designed to be
implanted next to the heart, avoiding the abdominal surgery
generally required to implant competing devices. The HeartWare
System is approved in the United
States for the intended use as a bridge to cardiac
transplantation in patients who are at risk of death from
refractory end-stage left ventricular heart failure, has received
CE Marking in the European Union and has been used to treat
patients in 37 countries. The device is also currently the subject
of a U.S. clinical trial for destination therapy. For additional
information, please visit the Company's website at
www.heartware.com.
HeartWare International, Inc. is a member of the Russell
2000® and its securities are publicly traded on The
NASDAQ Stock Market.
HEARTWARE, HVAD and HeartWare logos are registered trademarks
of HeartWare, Inc.
For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartware.com
Phone: +1 508 739 0864
SOURCE HeartWare International, Inc.